News & Topics

Thank you for your participation in Kickoff Symposium.(2020.1.24) 

2020/02/04

Thank you for your participation in Kickoff Symposium.(2020.1.24)   We would like to express our sincere gratitude and appreciation to all of you for the great contribution.

Our lab research proposal on HTLV-1 has been accepted for funding by [AMED] Strategic International Collaborative Research Program. 2019.12.16

2020/02/04

Our lab research proposal on HTLV-1 has been accepted for funding by [AMED] Strategic International Collaborative Research Program.  2019.12.16

Our paper “HTLV-1 contains a high CG dinucleotide content and is susceptible to the host antiviral protein ZAP” is published in Retrovirology. 2019.12.16

2020/02/03

Our paper “HTLV-1 contains a high CG dinucleotide content and is susceptible to the host antiviral protein ZAP” is published in Retrovirology. 2019.12.16

Miyazato P, Matsuo M, Tan B, Tokunaga M, Katsuya H, Islam S, Ito J, Murakawa Y, and Satou Y*. HTLV-1 contains high CG dinucleotide content and is susceptible to the host antiviral protein ZAP. Retrovirology, 16, 38, 2019.

Thank you for your participation in the 20th Kumamoto AIDS seminar.

2019/11/02

Thank you for your participation in the 20th Kumamoto AIDS seminar.
We would like to express our sincere gratitude and appreciation to all of you for the great contribution.

Program of the 20th AIDS Seminar has been updated

2019/10/25

Program of the 20th AIDS Seminar has been updated

New website completed

2019/08/08

New website completed

We are now the Joint Research Center for Human Retrovirus Infection, Kumamoto University Campus

2019/04/01

With the inauguration of a new research center, we have changed our name to the Joint Research Center for Human Retrovirus Infection, Kumamoto University Campus.

Selection for JSPS Core-to-Core Program

2019/04/01

Intercontinental Research and Educational Platform Aiming for Eradication of HIV/AIDS (Representative: Takamasa Ueno, Infection and Immunity) was selected for the JSPS Core-to-Core Program.

Selection for FY2019 AMED Research Program on HIV/AIDS

2019/04/01

Neutralizing Antibody-Mediated Treatment Strategy towards Cure of HIV-1 Infection (Representative: Shuzo Matsushita, Clinical Retrovirology) was selected for FY2019 AMED Research Program on HIV/AIDS.

Selection for FY2019 AMED Research Program on HIV/AIDS

2019/04/01

Creation of New Druggable Targets to Overcome HIV-1 Latency via Collaboration between High-Resolution Nucleic Acid Analyses and Leading-Edge Techniques for Viral Dynamics (Representative: Yorifumi Satou, Genomics and Transcript